Pure Global
NCT06043908

The Effect of 0.05% CsA Eye Drops on Post-refractive Surgery Dry Eye

The Effect of Topical 0.05% Cyclosporine Eye Drops on Post-refractive Surgery Dry Eye
Peking University Third Hospital·Phase 4·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Dry Eye
Drug/Device/Intervention
artificial tear eyedrops
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking University Third Hospital
Location
Beijing, China
Timeline & enrollment
Phase
Phase 4
Start date
Aug 31, 2022
End date
Dec 31, 2023
Enrollment
60 participants
Primary outcome

ocular surface disease index (OSDI),Tear break-up time (TBUT)(s),Corneal fluorescein staining (CFS),Schirmer I test (SIt) (mm/5 minutes),Lissamine green staining

Summary

The purpose of this study is to observe the effect of 0.05% cyclosporine eyedrops combined
 with artificial tears in patients with dry eyes after corneal refractive surgery and to
 observe the changes in ocular surface characteristics and tear inflammatory cytokines before
 and after treatment.

ICD-10 classifications
Ocular painAvulsion of eyeOther corneal deformitiesCorneal ulcerDry mouth, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06043908
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06043908 through Pure Global AI's free database. This Phase 4 trial is sponsored by Peking University Third Hospital and is currently Recruiting. The study focuses on Dry Eye. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.